Table 2.
Cancer gene expression profiling studies with up-regulated CA9 (FC>2) related to significantly activated focal adhesion pathway as identified by SPIA algorithm.
| Cancer type | Oncomine dataset | GEO ID | Study type* | SPIA—Focal adhesion (KEGG:04510) | |
|---|---|---|---|---|---|
| pGFDR** | Status*** | ||||
| Colorectal carcinoma progression | – | GSE1323 | T/M | 7.19E-02 | Activated |
| Colorectal carcinoma progression | – | GSE2509 | T/M | 7.24E-02 | Activated |
| Colorectal carcinoma | Skrzypczak Colorectal | GSE20916 | N/T | 8.11E-03 | Activated |
| Clear cell renal carcinoma | Yusenko Renal | GSE11151 | N/T | 4.24E-07 | Activated |
| Clear cell renal carcinoma | Lenburg Renal | GSE781 | N/T | 4.41E-02 | Activated |
| Clear cell renal carcinoma | Gumz Renal | GSE6344 | N/T | 5.25E-06 | Activated |
| Cervical squamous cell carcinoma | Scotto Cervix 2 | GSE9750 | N/T | 3.48E-03 | Activated |
| Esophageal carcinoma | Hu Esophagus | GSE20347 | N/T | 1.37E-06 | Activated |
| Pancreatic carcinoma | PlaceStatePei Pancreas | GSE16515 | N/T | 6.45E-05 | Activated |
*
Study type—T/M, primary tumor/metastasis; N/T, normal tissue/tumor.
**
pGFDR—false discovery adjusted global probability testing of the hypothesis that the differentially expressed genes significantly perturb this pathway. The lower the pGFDR value is the lower the probability of observing this or a higher number of differentially expressed genes just by chance.
***
Status—indicates whether the pathway is activated or inhibited in the conditions of the study.